drugcomb_oct2019_withdoses
| dc.contributor.affiliation | University of Helsinki - Zagidullin Bulat | |
| dc.contributor.author | Zagidullin Bulat | |
| dc.date.accessioned | 2025-03-24T15:17:00Z | |
| dc.date.issued | 2021-05-29 | |
| dc.date.issued | 2021-05-29 | |
| dc.description | Columns are: "block_id"|"drug_row"|"drug_col"|"drug_row_cid"|"drug_col_cid"|"conc_r"|"conc_c"|"inhibition"|"synergy_zip"|"synergy_bliss"|"synergy_loewe"|"synergy_hsa"|"cell_line_name"|"css_ri". * block_id refers to one experiment, that is testing two drugs in different doses in a single cell line. Biological replicates have different block_ids * drug_row and drug_col are commonly used drug names * drug_row_cid and drug_col_cid are CID drug identifiers * conc_c and conc_r are drug doses in uM * inhibition refers to percent growth inhibition as measured using a CTG cell viability assay (in most cases) * four synergy scores are calculated using distinct four null models. For further info please refer to Zagidullin 2019 in Nucleic Acids Research * CSS_RI is a combination sensitivity score, for more info refer to Malyutina 2019 in PLoS computational biology | |
| dc.identifier | https://doi.org/10.5281/zenodo.4843919 | |
| dc.identifier.uri | https://hydatakatalogi-test-24.it.helsinki.fi/handle/123456789/9886 | |
| dc.rights | Open | |
| dc.rights.license | cc-by-4.0 | |
| dc.subject | drug combinations | |
| dc.subject | drug synergy | |
| dc.subject | drug repurposing | |
| dc.subject | cancer | |
| dc.title | drugcomb_oct2019_withdoses | |
| dc.type | dataset | |
| dc.type | dataset |